Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine

2 Aug 2013

Abstract excerpt

The prognosis of patients after allogeneic hematopoietic stem cell transplantation (HSCT) is still not satisfactory because, while treatment-related mortalities have decreased, relapse after HSCT remains a major concern. The effectiveness of allogeneic HSCT for hematological malignancies is the result of immunologic rejection of recipient leukemia cells by donor T cells, known as the graft-versus-leukemia (GVL)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Childhood Cancer Survivors' Quality of Life
Share to Renal and related cancers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23912610
DOI: 10.1038/bcj.2013.29

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccinePMID 23912610Read ↗

Graft-versus-leukemia effects of Wilms' tumor 1 protein-specific cytotoxic T lymphocytes in patients with chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation.Semantic proximity Read ↗

“Wilms Tumor Protein 1” (WT1) Peptide Vaccination-induced Complete Remission in a Patient With Acute Myeloid Leukemia Is Accompanied by the Emergence of a Predominant T-cell Clone Both in Blood and Bone MarrowSemantic proximity Read ↗

Safety and persistence of WT1-specific T-cell receptor gene−transduced lymphocytes in patients with AML and MDSSemantic proximity Read ↗

Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients.Semantic proximity Read ↗

In vitro stimulation with WT1 peptide-loaded Epstein-Barr virus-positive B cells elicits high frequencies of WT1 peptide-specific T cells with in vitro and in vivo tumoricidal activity.Semantic proximity Read ↗

DNA vaccination induces WT1-specific T-cell responses with potential clinical relevanceSemantic proximity Read ↗

Spontaneous high clonal expansion of Wilms’ tumor gene 1 (WT1)-specific cytotoxic T-lymphocytes in patients with WT1-expressing solid tumorSemantic proximity Read ↗

Graft-versus-leukemia reactions in allogeneic chimerasSemantic proximity Read ↗

Two distinct HLA-A0201–presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTLSemantic proximity Read ↗

Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination.Semantic proximity Read ↗

Synthetic tumor‐specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual diseaseSemantic proximity Read ↗

A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.